BioCentury

7:00 AM GMT, Jun 14, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Other News

Myriad Pharmaceuticals cancer news

Myriad restructured and reduced headcount by 21 (13%) to about 140 to focus on its cancer pipeline. The company's lead cancer compound is

Read the full 235 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.